Brief: Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Co's EndeavorRx for Pediatric ADHD Patients in Japan
26/02/2024 13:54
Feb 26 (Reuters) - Akili Inc AKLI.O :
* AKILI ANNOUNCES POSITIVE RESULTS FROM SHIONOGI’S PHASE 3
CLINICAL TRIAL OF LOCALIZED VERSION OF AKILI’S ENDEAVORRX® FOR
PEDIATRIC ADHD PATIENTS IN JAPAN
* AKILI INC - JAPANESE PRODUCT NOW UNDER REVIEW FOR
NATIONWIDE
MARKETING APPROVAL
* AKILI INC - SYMPTOM IMPROVEMENTS WERE SUSTAINED EVEN AFTER
TWO
CYCLES OF SDT-001 USE, WITH NO SAFETY CONCERNS NOTED
Source text for Eikon: ID:nBw4Gt4T4a
Further company coverage: AKLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akili
See all newsBrief: Akili Announces FDA Authorization Of Endeavorotc, The First FDA Clearance Of A Digital Treatment For Adults With Adhd Through A Video Game
Brief: Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement To Establish Leading Digital Health Company
Akili Inc reports results for the quarter ended in March - Earnings Summary
Akili Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery